Bristol Gross Profit from 2010 to 2025

BMY Stock

USD 61.07 0.65 1.08%

Bristol Myers Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit is likely to outpace its year average in 2025. Gross Profit is the profit Bristol Myers Squibb makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

1987-03-31

Previous Quarter

8.9 B

Current Value

7.5 B

Quarterly Volatility

2 B

Black Monday

Oil Shock

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Bristol Myers financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bristol Myers' main balance sheet or income statement drivers, such as Depreciation And Amortization of 10.1 B, Interest Expense of 2 B or Selling General Administrative of 8.8 B, as well as many indicators such as Price To Sales Ratio of 2.95, Dividend Yield of 0.0274 or PTB Ratio of 6.94. Bristol financial statements analysis is a perfect complement when working with Bristol Myers Valuation or Volatility modules.

Check out the analysis of Bristol Myers Correlation against competitors.

Latest Bristol Myers' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Bristol Myers Squibb over the last few years. Gross profit is a required income statement account that reflects total revenue of Bristol Myers Squibb minus its cost of goods sold. It is profit before Bristol Myers operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Bristol Myers' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bristol Myers' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 36.35 B

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Bristol Gross Profit Regression Statistics

	Arithmetic Mean	21,609,659,375
	Geometric Mean	18,744,396,738
	Coefficient Of Variation	52.74
	Mean Deviation	10,298,324,219
	Median	16,014,000,000
	Standard Deviation	11,397,800,075
	Sample Variance	129909846.5T
	Range	32.8B
	R-Value	0.91
	Mean Square Error	23043448.1T
	R-Squared	0.83
	Slope	2,186,885,662
	Total Sum of Squares	1948647698.2T

Bristol Gross Profit History

	2025	38.2 B
	2024	36.4 B
	2023	34.3 B
	2022	36 B
	2021	36.4 B
	2020	30.7 B
	2019	18.1 B

Other Fundumenentals of Bristol Myers Squibb

Gross Profit Margin

Bristol Myers Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Good Will	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Short Term Investments	Capital Stock	Common Stock	Long Term Debt	Treasury Stock	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Total Permanent Equity	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital
Total Assets		0.85	0.95	-0.14	0.78	0.96	0.98	0.95	0.78	0.95	0.63	0.04	0.89	0.89	0.95	-0.77	0.83	0.39	-0.97	0.38	0.97	0.93	0.78	-0.49	-0.38	0.91	0.98	0.81
Total Stockholder Equity	0.85		0.66	0.16	0.56	0.74	0.74	0.72	0.79	0.93	0.5	0.38	0.67	0.67	0.69	-0.47	0.6	0.56	-0.82	0.24	0.75	0.66	0.8	-0.5	-0.28	0.79	0.85	0.8
Net Debt	0.95	0.66		-0.31	0.82	0.98	0.99	0.93	0.71	0.85	0.58	-0.18	0.92	0.92	1.0	-0.86	0.89	0.25	-0.95	0.48	0.98	0.99	0.67	-0.49	-0.44	0.89	0.94	0.73
Retained Earnings	-0.14	0.16	-0.31		-0.14	-0.14	-0.23	-0.14	-0.11	-0.13	0.18	0.54	-0.36	-0.36	-0.31	0.18	-0.29	-0.4	0.25	-0.49	-0.32	-0.37	-0.08	0.39	-0.02	-0.27	-0.24	-0.1
Net Receivables	0.78	0.56	0.82	-0.14		0.88	0.82	0.86	0.82	0.64	0.66	-0.17	0.81	0.81	0.81	-0.95	0.82	-0.03	-0.79	0.52	0.8	0.86	0.35	-0.35	-0.54	0.73	0.77	0.58
Good Will	0.96	0.74	0.98	-0.14	0.88		0.98	0.96	0.78	0.86	0.67	-0.08	0.91	0.91	0.97	-0.9	0.89	0.19	-0.95	0.43	0.96	0.97	0.66	-0.44	-0.46	0.89	0.95	0.74
Total Liab	0.98	0.74	0.99	-0.23	0.82	0.98		0.96	0.74	0.89	0.64	-0.08	0.91	0.91	0.99	-0.84	0.87	0.28	-0.97	0.43	0.99	0.97	0.71	-0.48	-0.42	0.91	0.96	0.77
Total Current Assets	0.95	0.72	0.93	-0.14	0.86	0.96	0.96		0.75	0.82	0.73	-0.01	0.88	0.88	0.94	-0.86	0.81	0.19	-0.91	0.38	0.93	0.93	0.59	-0.39	-0.4	0.86	0.91	0.76
Short Term Debt	0.78	0.79	0.71	-0.11	0.82	0.78	0.74	0.75		0.8	0.57	0.12	0.78	0.78	0.71	-0.7	0.77	0.4	-0.82	0.49	0.75	0.75	0.61	-0.46	-0.38	0.8	0.81	0.67
Intangible Assets	0.95	0.93	0.85	-0.13	0.64	0.86	0.89	0.82	0.8		0.49	0.15	0.81	0.81	0.86	-0.6	0.75	0.6	-0.95	0.39	0.91	0.84	0.88	-0.62	-0.32	0.92	0.97	0.85
Accounts Payable	0.63	0.5	0.58	0.18	0.66	0.67	0.64	0.73	0.57	0.49		0.05	0.7	0.7	0.59	-0.72	0.67	-0.21	-0.59	-0.05	0.56	0.58	0.35	-0.01	-0.22	0.51	0.53	0.32
Short Term Investments	0.04	0.38	-0.18	0.54	-0.17	-0.08	-0.08	-0.01	0.12	0.15	0.05		-0.14	-0.14	-0.12	0.3	-0.19	0.24	0.06	-0.22	-0.1	-0.19	0.22	0.09	0.04	0.1	0.03	0.31
Capital Stock	0.89	0.67	0.92	-0.36	0.81	0.91	0.91	0.88	0.78	0.81	0.7	-0.14		1.0	0.92	-0.84	0.95	0.27	-0.91	0.48	0.92	0.93	0.62	-0.47	-0.43	0.85	0.89	0.62
Common Stock	0.89	0.67	0.92	-0.36	0.81	0.91	0.91	0.88	0.78	0.81	0.7	-0.14	1.0		0.92	-0.84	0.95	0.27	-0.91	0.48	0.92	0.93	0.62	-0.47	-0.43	0.85	0.89	0.62
Long Term Debt	0.95	0.69	1.0	-0.31	0.81	0.97	0.99	0.94	0.71	0.86	0.59	-0.12	0.92	0.92		-0.84	0.88	0.28	-0.96	0.48	0.99	0.98	0.68	-0.53	-0.45	0.92	0.95	0.77
Treasury Stock	-0.77	-0.47	-0.86	0.18	-0.95	-0.9	-0.84	-0.86	-0.7	-0.6	-0.72	0.3	-0.84	-0.84	-0.84		-0.87	0.14	0.79	-0.41	-0.81	-0.89	-0.35	0.29	0.45	-0.68	-0.75	-0.5
Property Plant Equipment	0.83	0.6	0.89	-0.29	0.82	0.89	0.87	0.81	0.77	0.75	0.67	-0.19	0.95	0.95	0.88	-0.87		0.14	-0.87	0.55	0.86	0.9	0.62	-0.5	-0.54	0.79	0.84	0.56
Current Deferred Revenue	0.39	0.56	0.25	-0.4	-0.03	0.19	0.28	0.19	0.4	0.6	-0.21	0.24	0.27	0.27	0.28	0.14	0.14		-0.42	0.26	0.38	0.26	0.63	-0.51	0.14	0.48	0.48	0.55
Net Tangible Assets	-0.97	-0.82	-0.95	0.25	-0.79	-0.95	-0.97	-0.91	-0.82	-0.95	-0.59	0.06	-0.91	-0.91	-0.96	0.79	-0.87	-0.42		-0.45	-0.98	-0.95	-0.81	0.59	0.39	-0.94	-0.99	-0.82
Total Permanent Equity	0.38	0.24	0.48	-0.49	0.52	0.43	0.43	0.38	0.49	0.39	-0.05	-0.22	0.48	0.48	0.48	-0.41	0.55	0.26	-0.45		0.5	0.53	0.17	-0.74	-0.77	0.52	0.49	0.4
Long Term Debt Total	0.97	0.75	0.98	-0.32	0.8	0.96	0.99	0.93	0.75	0.91	0.56	-0.1	0.92	0.92	0.99	-0.81	0.86	0.38	-0.98	0.5		0.98	0.72	-0.58	-0.43	0.94	0.98	0.81
Capital Surpluse	0.93	0.66	0.99	-0.37	0.86	0.97	0.97	0.93	0.75	0.84	0.58	-0.19	0.93	0.93	0.98	-0.89	0.9	0.26	-0.95	0.53	0.98		0.62	-0.53	-0.43	0.89	0.94	0.72
Deferred Long Term Liab	0.78	0.8	0.67	-0.08	0.35	0.66	0.71	0.59	0.61	0.88	0.35	0.22	0.62	0.62	0.68	-0.35	0.62	0.63	-0.81	0.17	0.72	0.62		-0.5	-0.11	0.76	0.78	0.77
Long Term Investments	-0.49	-0.5	-0.49	0.39	-0.35	-0.44	-0.48	-0.39	-0.46	-0.62	-0.01	0.09	-0.47	-0.47	-0.53	0.29	-0.5	-0.51	0.59	-0.74	-0.58	-0.53	-0.5		0.54	-0.64	-0.62	-0.59
Short Long Term Debt	-0.38	-0.28	-0.44	-0.02	-0.54	-0.46	-0.42	-0.4	-0.38	-0.32	-0.22	0.04	-0.43	-0.43	-0.45	0.45	-0.54	0.14	0.39	-0.77	-0.43	-0.43	-0.11	0.54		-0.48	-0.41	-0.35
Cash And Equivalents	0.91	0.79	0.89	-0.27	0.73	0.89	0.91	0.86	0.8	0.92	0.51	0.1	0.85	0.85	0.92	-0.68	0.79	0.48	-0.94	0.52	0.94	0.89	0.76	-0.64	-0.48		0.95	0.89
Net Invested Capital	0.98	0.85	0.94	-0.24	0.77	0.95	0.96	0.91	0.81	0.97	0.53	0.03	0.89	0.89	0.95	-0.75	0.84	0.48	-0.99	0.49	0.98	0.94	0.78	-0.62	-0.41	0.95		0.85
Net Working Capital	0.81	0.8	0.73	-0.1	0.58	0.74	0.77	0.76	0.67	0.85	0.32	0.31	0.62	0.62	0.77	-0.5	0.56	0.55	-0.82	0.4	0.81	0.72	0.77	-0.59	-0.35	0.89	0.85

Click cells to compare fundamentals

About Bristol Myers Financial Statements

Bristol Myers investors use historical fundamental indicators, such as Bristol Myers' Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Bristol Myers. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Gross Profit	36.4 B	38.2 B
Gross Profit Margin	0.75	0.80

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Bristol Stock Analysis

When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC